JP-WXDC@EC2611A

CHINA OIL & GAS

PETRO-KING

DZUG

CHK OIL

MANY IDEA CLOUD

HAO TIAN INTL

JY GAS

COSCO SHIP DEV

GLOBAL UIN

BG BLUE SKY

02268

China Merchants Jinling International released a research report, maintaining a "Buy" rating for WUXI XDC, believing that its investment and financing as well as BD transactions in the global CXO sector remain active. It is expected that comprehensive orders will grow by more than 20% from 2025 to 2027, with revenue and adjusted net profit forecasts slightly lowered by 1% to 3%. The target price is HKD 91, corresponding to a price-to-earnings ratio of 42 times for 2026, and the company continues to be recommended as a key target in the CXO industry

AASTOCKS

WUXI XDC

"Major Banks" CMB International: WUXI XDC's global CXO track investment and financing, BD transactions continue to show high activity, maintaining a "Buy" rating

159849

588860

603259

159859

02269

512290

Morgan Stanley predicts that WUXI XDC's stock price will rise in the next 30 days, as the recent price drop has made short-term valuations more attractive. WuXi AppTec announced a significant external licensing agreement involving its payload connector technology platform, which is expected to enhance sales and profitability. Morgan Stanley has set a target price of 86 yuan for the stock, with a rating of "Overweight."

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

WuXi AppTec

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

WUXI BIO

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Morgan Stanley: WUXI XDC stock price will absolutely rise in the next 30 days

510660

159992

516930

Wuxi XDC enters strategic collaboration with Earendil Labs

marketscreener

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Wuxi XDC enters strategic collaboration with Earendil Labs

159102

159615

513700

520690

513120

520880

159316

Citi released a report stating that WUXI BIO and WUXI XDC fell approximately 7% and 8% respectively on Thursday, while Hong Kong CRO/CDMO companies overall dropped about 2% to 9%. Analysts believe that this decline is not driven by fundamentals, but rather a result of position adjustments and capital flows. The current pullback is viewed as a technical short-term fluctuation, and the lack of catalysts in the market may lead to overselling of industry leaders, providing a more attractive entry point for investors holding for 3 to 12 months

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

In "The Big Banks," Citigroup: WUXI BIO and WUXI XDC fell on Thursday due to non-fundamental drivers

00881

02865

03931

06160

00400

02509

02659

02096

ZHONGSHENG HLDG(00881) fell 10.76%, with a trading turnover 324.3 Million HKD, and a year-to-date fell 10.8%. DRINDA(02865) fell 9.32%, with a trading turnover 451.5 Million HKD, and a year-to-date rose 51.2%. CALB(03931) fell 9.26%, with a trading turnover 179.9 Million HKD, and a year-to-date fell 0.1%.

Top Gainers & Losers

ZHONGSHENG HLDG

DRINDA

CALB

BEONE MEDICINES

INGDAN

QYUNS-B

BAO PHARMA-B

SIMCERE PHARMA

Top 10 HK Stock Losers (2.26)

XPEV

688235

03750

688347

01347

Pharmaceutical stocks fell sharply, with WUXI XDC down about 9% and BEONE MEDICINES down about 9%. Technology stocks and automotive stocks also declined, with Bilibili down about 5% and XPeng down about 5%. Semiconductor stocks fell, with HUA HONG SEMI down about 5%

Wallstreetcn

XPeng

BeOne Medicines

CATL

Hua Hong

HUA HONG SEMI

The Hang Seng Index closed down 1.44%, the Hang Seng Tech Index fell 2.87%, and CATL dropped about 6%

513060

Morgan Stanley has lowered the target price for WUXI XDC to 86 yuan, with a rating of "Overweight." Due to a decline in operating profit margins, the bank has reduced its earnings forecast for 2026 to 2030 by 1% to 2%. Nevertheless, it is expected that WUXI XDC's adjusted net profit compound annual growth rate from 2024 to 2027 will reach 36%, higher than global peers, demonstrating the company's profit growth potential and industry leadership

Bosera Hang Seng Health Care ETF(QDII)

Morgan Stanley lowered the target price for WuXi XDC to 86 yuan, rating it as "Overweight."

02359

Macquarie's research report indicates that WuXi AppTec has been included in the U.S. 1260H list, but this list does not constitute an investment ban and mainly affects defense contracts. The report suggests that investors should buy WuXi AppTec during price corrections and maintains its "outperform" rating with a target price of 132 yuan. Meanwhile, WUXI XDC is also recommended with a target price of 73 yuan

WUXI APPTEC

Macquarie urges to buy WuXi AppTec, expected to be included in the US 1260H list without being affected

Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy

Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy

Nomura's research report indicates that WUXI BIO is expected to see a revenue increase of 16.7% to RMB 21.8 billion in 2025, exceeding market expectations. The gross margin is expected to improve to 46%, and net profit is projected to grow by 45.3% to RMB 5.7 billion. The firm has raised the target price to HKD 50.54 and maintains a "Buy" rating, believing that its subsidiary WUXI XDC will make a significant contribution to revenue growth

Nomura raises WUXI BIO's target price to 50.54 yuan, with preliminary annual performance exceeding expectations

Nomura has raised the target price for WUXI XDC to HKD 87.73, expecting a 47% increase in profits by 2026. Although the revenue and profit forecasts for 2025 have been lowered by 4.5% and 8.7% respectively, the revenue for 2026 is expected to increase by 37% year-on-year to RMB 8.1 billion, mainly benefiting from more projects entering the clinical trial phase. The gross margin is expected to expand to 36.5%, and the operating profit margin will rise to 29.3%

Nomura raises WUXI XDC's target price to 87.73 yuan, expects profit to rise by 47% this year

Wuxi XDC Cayman Inc. and BioDlink International Company Limited have announced the dispatch of a composite document regarding a voluntary cash offer by Citigroup Global Markets Asia Limited for all shares of Wuxi XDC not already owned by the offeror. The update includes the cancellation of all outstanding share options, with further announcements to follow as the transaction progresses.

Reuters

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares US Pharma

E Fund CSI New Energy ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Biotechnology ETF

VG Health

Wuxi XDC Cayman Inc. Sends Out Composite Document for Voluntary Cash Offer

01875

WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. (HK:1875), excluding shares already held by the offeror. The offer starts on 12 February 2026, with key deadlines extending to mid-March. The latest analyst rating for TOT BIOPHARM is a Hold, with a price target of HK$4.50. TOT BIOPHARM focuses on developing oncology and biologic therapies and is listed on the Hong Kong Stock Exchange, with a market cap of HK$3.25B.

Tip Ranks

BIODLINK-B

WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM

688981

83192

02313

JP Morgan listed the companies affected by the appreciation of the RMB on the earnings of Chinese stocks, indicating that a 5% appreciation of the RMB against the USD will negatively impact the net profits of several companies. The affected companies include SHENZHOU INTL, Super Ocean International, SMIC, USISH, COWELL, Longi Green Energy, SINOCERA MATERIAL, Zhejiang Dingli, Sany, XCMG, WUXI BIO, WUXI XDC, Jereh Holdings, and Sinopec Oilfield Service, with an expected impact range of 7% to 15%

SMIC

A BOS RMB MM-R

SHENZHOU INTL

Sany

A BOS RMB MM

SINOCERA MATERIAL

A VP RMB MM

USISH

COWELL

XCMG

JP Morgan lists the Chinese stocks that are most negatively impacted by the appreciation of the RMB (Table)

159570

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

SKB BIO-B

KELUN PHARMA

HENLIUS

WEIGAO GROUP

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

HYGEIA HEALTH

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

JP-WXDC@EC2611A(25507.HK)

"Major Banks" CMB International: WUXI XDC's global CXO track investment and financing, BD transactions continue to show high activity, maintaining a "Buy" rating

Morgan Stanley: WUXI XDC stock price will absolutely rise in the next 30 days

Wuxi XDC enters strategic collaboration with Earendil Labs

In "The Big Banks," Citigroup: WUXI BIO and WUXI XDC fell on Thursday due to non-fundamental drivers

Top 10 HK Stock Losers (2.26)